Targeted Therapies for Hepatocellular Carcinoma
TLDR
Identification of oncogenes that mediate tumor progression, and trials that monitor their products as biomarkers, might lead to personalized therapy; reagents that interfere with signaling pathways required for HCC progression might be used to treat selected populations, and thereby maximize the efficacy and cost benefit.About:
This article is published in Gastroenterology.The article was published on 2011-05-01 and is currently open access. It has received 402 citations till now. The article focuses on the topics: Sorafenib & Targeted therapy.read more
Citations
More filters
Journal ArticleDOI
Effects of SASH1 on melanoma cell proliferation and apoptosis in vitro
TL;DR: Results indicated that the tumor suppressive effects of the SASH1 gene derived from G2/M arrest in A-375 cells, and that the phosphorylation of Cdc2 or the disruption of cyclin B-Cdc2 binding may be responsible for the G2-M arrest.
Journal ArticleDOI
Development and novel therapeutics in hepatocellular carcinoma: a review.
P. V. Ingle,Sarah Zakiah Binti Samsudin,Pei Qi Chan,Mei Kei Ng,Li Xuan Heng,Siu Ching Yap,Amy Siaw Hui Chai,Audrey San Ying Wong +7 more
TL;DR: This review summarizes the epidemiological trend, risk factors, prevention strategies such as vaccination, staging, current novel therapeutics, including the drugs under clinical trials, and future therapeutic trends for hepatocellular carcinoma (HCC).
Journal ArticleDOI
New progress of non-surgical treatments for hepatocellular carcinoma
Jiwen Cheng,Yi Lv +1 more
TL;DR: The current non-surgical treatments in HCC and the new advances in this field are reviewed, including TACE and sorafenib which could improve survival for selected patients and gene therapy and immunotherapy which are still in testing phases.
Journal ArticleDOI
Proteomic Analysis and NIR-II Imaging of MCM2 Protein in Hepatocellular Carcinoma
Jing Yang,Jing Yang,Xie Qi,Xie Qi,Hui Zhou,Lei Chang,Wei Wei,Wang Yin,Wang Yin,Hong Li,Zixin Deng,Yuling Xiao,Junzhu Wu,Ping Xu,Ping Xu,Ping Xu,Xuechuan Hong,Xuechuan Hong +17 more
TL;DR: Of the upregulated tumor-related proteins, minichromosome maintenance 2 (MCM2), a DNA replication licensing factor, was one of the most significantly altered proteins, and its overexpression was confirmed using tissue microarray and the first small molecule-based MCM2-targeted NIR-II probe CH1055-MCM 2 was concisely generated and subsequently evaluated in mice bearing HepG2 xenografts.
Journal ArticleDOI
Functional genomics identified a novel protein tyrosine phosphatase receptor type f‐mediated growth inhibition in hepatocarcinogenesis
Rabindranath Bera,Chih-Yung Chiou,Ming-Chin Yu,Jei-Ming Peng,Chung-Ru He,Chih-Yun Hsu,Hsiao-Ling Huang,Uda Ho,Shi-Ming Lin,Yu-Jr Lin,Sen-Yung Hsieh,Sen-Yung Hsieh +11 more
TL;DR: It is found that PTPRF was induced during cell proliferation by cell‐cell contact and quenched the activated ERK‐dependent proliferation signaling to prevent cell hyperproliferation and tumor initiation.
References
More filters
Journal ArticleDOI
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Patrick Therasse,Susan G. Arbuck,Elizabeth Eisenhauer,Jantien Wanders,Richard Kaplan,Larry Rubinstein,Jaap Verweij,Martine Van Glabbeke,Allan T. van Oosterom,Michaele C. Christian,S. Gwyther +10 more
TL;DR: A model by which a combined assessment of all existing lesions, characterized by target lesions and nontarget lesions, is used to extrapolate an overall response to treatment is proposed, which is largely validated by the Response Evaluation Criteria in Solid Tumors Group and integrated into the present guidelines.
Journal ArticleDOI
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet,Sergio Ricci,Vincenzo Mazzaferro,Philip Hilgard,Edward Gane,Jean-Frédéric Blanc,André Cosme de Oliveira,Armando Santoro,Jean-Luc Raoul,Alejandro Forner,Myron Schwartz,Camillo Porta,Stefan Zeuzem,Luigi Bolondi,Tim F. Greten,Peter R. Galle,Jean Francois Seitz,Ivan Borbath,Dieter Häussinger,Tom Giannaris,Minghua Shan,M. Moscovici,D. Voliotis,Jordi Bruix +23 more
TL;DR: In patients with advanced hepatocellular carcinoma, median survival and the time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than for those given placebo.
Journal ArticleDOI
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
J. Guillermo Paez,Pasi A. Jänne,Pasi A. Jänne,Jeffrey C. Lee,Sean Tracy,Heidi Greulich,Heidi Greulich,Stacey Gabriel,Paula Herman,Frederic J. Kaye,Neal I. Lindeman,Titus J. Boggon,Katsuhiko Naoki,Hidefumini Sasaki,Yoshitaka Fujii,Michael J. Eck,William R. Sellers,William R. Sellers,William R. Sellers,Bruce E. Johnson,Bruce E. Johnson,Matthew Meyerson,Matthew Meyerson +22 more
TL;DR: Results suggest that EGFR mutations may predict sensitivity to gefitinib, and treatment with the EGFR kinase inhibitor gefitsinib causes tumor regression in some patients with NSCLC, more frequently in Japan.
Journal ArticleDOI
Cancer Statistics, 2009
TL;DR: The most recent data on cancer incidence, mortality, and survival from the American Cancer Society (ACS) is presented in this paper, where the authors compare the three major cancer sites in men (lung, prostate, and colon and rectum [colorectum]) and in two major cancers sites in women (breast and colorectal) over a 15-year period.
Journal ArticleDOI
Management of hepatocellular carcinoma: An update
Jordi Bruix,Morris Sherman +1 more
TL;DR: The American Association for the Study of Liver Diseases (AASLD) practice guidelines on the management of hepatocellular carcinoma (HCC) were updated in 2010 as discussed by the authors.
Related Papers (5)
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet,Sergio Ricci,Vincenzo Mazzaferro,Philip Hilgard,Edward Gane,Jean-Frédéric Blanc,André Cosme de Oliveira,Armando Santoro,Jean-Luc Raoul,Alejandro Forner,Myron Schwartz,Camillo Porta,Stefan Zeuzem,Luigi Bolondi,Tim F. Greten,Peter R. Galle,Jean Francois Seitz,Ivan Borbath,Dieter Häussinger,Tom Giannaris,Minghua Shan,M. Moscovici,D. Voliotis,Jordi Bruix +23 more